Redhill Net Debt vs Accounts Payable Analysis

RDHL Stock

USD 6.74 0.34 5.31%

Redhill Biopharma financial indicator trend analysis is much more than just breaking down Redhill Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Redhill Biopharma is a good investment. Please check the relationship between Redhill Biopharma Net Debt and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.

Net Debt vs Accounts Payable

Net Debt vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Redhill Biopharma Net Debt account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Redhill Biopharma's Net Debt and Accounts Payable is 0.58. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Redhill Biopharma, assuming nothing else is changed. The correlation between historical values of Redhill Biopharma's Net Debt and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Redhill Biopharma are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Debt i.e., Redhill Biopharma's Net Debt and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.58

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Accounts Payable

An accounting item on the balance sheet that represents Redhill Biopharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Redhill Biopharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Redhill Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Redhill Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.At this time, Redhill Biopharma's Enterprise Value Over EBITDA is quite stable compared to the past year. Enterprise Value Multiple is expected to rise to 9.28 this year, although the value of Issuance Of Capital Stock will most likely fall to about 13.3 M.

Redhill Biopharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Other Liab	Accounts Payable	Cash	Long Term Debt	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Total Liab	Preferred Stock Total Equity	Intangible Assets	Common Stock	Property Plant Equipment	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total
Total Assets		0.88	0.75	0.6	0.87	0.53	0.48	-0.13	-0.01	0.18	0.91	0.28	0.95	-0.22	0.56	-0.24	0.83	0.75	-0.56	0.94	0.51	0.5	0.32	0.91	0.54	0.81
Other Current Liab	0.88		0.91	0.64	0.76	0.17	0.6	0.17	-0.34	0.08	0.99	0.0	0.94	0.08	0.7	-0.66	0.89	0.95	-0.75	0.92	0.6	0.76	-0.12	0.99	0.63	0.74
Total Current Liabilities	0.75	0.91		0.49	0.49	0.11	0.53	0.14	-0.31	0.19	0.91	0.01	0.79	0.06	0.59	-0.73	0.88	0.92	-0.71	0.75	0.32	0.65	-0.14	0.91	0.55	0.42
Other Liab	0.6	0.64	0.49		0.61	0.38	0.41	0.3	-0.46	-0.14	0.63	-0.13	0.67	0.25	0.61	-0.36	0.54	0.5	-0.54	0.67	0.59	0.67	-0.07	0.62	0.49	0.64
Accounts Payable	0.87	0.76	0.49	0.61		0.4	0.57	0.12	0.03	0.06	0.74	-0.01	0.85	0.04	0.67	-0.1	0.68	0.58	-0.62	0.87	0.6	0.61	0.25	0.74	0.67	0.9
Cash	0.53	0.17	0.11	0.38	0.4		0.04	-0.39	0.26	-0.09	0.24	0.43	0.32	-0.43	-0.02	0.46	0.2	-0.08	0.0	0.32	0.08	-0.15	0.8	0.21	0.09	0.33
Long Term Debt	0.48	0.6	0.53	0.41	0.57	0.04		0.65	-0.27	-0.23	0.53	-0.5	0.53	0.58	0.88	-0.38	0.68	0.49	-0.9	0.53	0.09	0.79	-0.17	0.53	0.94	0.39
Common Stock Shares Outstanding	-0.13	0.17	0.14	0.3	0.12	-0.39	0.65		-0.34	-0.17	0.04	-0.93	-0.02	0.99	0.66	-0.39	0.16	0.12	-0.71	-0.02	0.01	0.75	-0.49	0.05	0.7	-0.06
Short Term Investments	-0.01	-0.34	-0.31	-0.46	0.03	0.26	-0.27	-0.34		0.62	-0.32	0.3	-0.26	-0.33	-0.41	0.73	-0.32	-0.4	0.28	-0.26	-0.26	-0.5	0.77	-0.32	-0.15	-0.22
Other Current Assets	0.18	0.08	0.19	-0.14	0.06	-0.09	-0.23	-0.17	0.62		0.1	0.19	0.06	-0.18	-0.14	0.09	0.05	0.17	0.05	0.04	0.01	-0.09	0.31	0.1	-0.1	-0.1
Total Liab	0.91	0.99	0.91	0.63	0.74	0.24	0.53	0.04	-0.32	0.1		0.13	0.96	-0.05	0.65	-0.61	0.91	0.94	-0.67	0.95	0.56	0.67	-0.06	1.0	0.56	0.75
Preferred Stock Total Equity	0.28	0.0	0.01	-0.13	-0.01	0.43	-0.5	-0.93	0.3	0.19	0.13		0.17	-0.95	-0.51	0.28	0.0	0.04	0.52	0.17	0.04	-0.61	0.49	0.12	-0.54	0.16
Intangible Assets	0.95	0.94	0.79	0.67	0.85	0.32	0.53	-0.02	-0.26	0.06	0.96	0.17		-0.11	0.68	-0.45	0.89	0.87	-0.6	1.0	0.59	0.63	0.03	0.96	0.55	0.87
Common Stock	-0.22	0.08	0.06	0.25	0.04	-0.43	0.58	0.99	-0.33	-0.18	-0.05	-0.95	-0.11		0.59	-0.35	0.07	0.04	-0.64	-0.11	-0.03	0.69	-0.51	-0.05	0.63	-0.13
Property Plant Equipment	0.56	0.7	0.59	0.61	0.67	-0.02	0.88	0.66	-0.41	-0.14	0.65	-0.51	0.68	0.59		-0.5	0.8	0.63	-0.9	0.68	0.22	0.9	-0.3	0.65	0.91	0.55
Total Stockholder Equity	-0.24	-0.66	-0.73	-0.36	-0.1	0.46	-0.38	-0.39	0.73	0.09	-0.61	0.28	-0.45	-0.35	-0.5		-0.56	-0.79	0.55	-0.43	-0.34	-0.68	0.76	-0.63	-0.33	-0.2
Property Plant And Equipment Net	0.83	0.89	0.88	0.54	0.68	0.2	0.68	0.16	-0.32	0.05	0.91	0.0	0.89	0.07	0.8	-0.56		0.87	-0.74	0.88	0.22	0.67	-0.09	0.9	0.69	0.61
Net Debt	0.75	0.95	0.92	0.5	0.58	-0.08	0.49	0.12	-0.4	0.17	0.94	0.04	0.87	0.04	0.63	-0.79	0.87		-0.65	0.85	0.51	0.69	-0.32	0.95	0.49	0.61
Retained Earnings	-0.56	-0.75	-0.71	-0.54	-0.62	0.0	-0.9	-0.71	0.28	0.05	-0.67	0.52	-0.6	-0.64	-0.9	0.55	-0.74	-0.65		-0.59	-0.22	-0.92	0.22	-0.67	-0.96	-0.4
Non Current Assets Total	0.94	0.92	0.75	0.67	0.87	0.32	0.53	-0.02	-0.26	0.04	0.95	0.17	1.0	-0.11	0.68	-0.43	0.88	0.85	-0.59		0.61	0.63	0.03	0.94	0.55	0.9
Non Currrent Assets Other	0.51	0.6	0.32	0.59	0.6	0.08	0.09	0.01	-0.26	0.01	0.56	0.04	0.59	-0.03	0.22	-0.34	0.22	0.51	-0.22	0.61		0.46	-0.11	0.57	0.13	0.75
Other Assets	0.5	0.76	0.65	0.67	0.61	-0.15	0.79	0.75	-0.5	-0.09	0.67	-0.61	0.63	0.69	0.9	-0.68	0.67	0.69	-0.92	0.63	0.46		-0.44	0.68	0.84	0.52
Cash And Short Term Investments	0.32	-0.12	-0.14	-0.07	0.25	0.8	-0.17	-0.49	0.77	0.31	-0.06	0.49	0.03	-0.51	-0.3	0.76	-0.09	-0.32	0.22	0.03	-0.11	-0.44		-0.08	-0.08	0.07
Net Receivables	0.91	0.99	0.91	0.62	0.74	0.21	0.53	0.05	-0.32	0.1	1.0	0.12	0.96	-0.05	0.65	-0.63	0.9	0.95	-0.67	0.94	0.57	0.68	-0.08		0.55	0.75
Common Stock Total Equity	0.54	0.63	0.55	0.49	0.67	0.09	0.94	0.7	-0.15	-0.1	0.56	-0.54	0.55	0.63	0.91	-0.33	0.69	0.49	-0.96	0.55	0.13	0.84	-0.08	0.55		0.41
Non Current Liabilities Total	0.81	0.74	0.42	0.64	0.9	0.33	0.39	-0.06	-0.22	-0.1	0.75	0.16	0.87	-0.13	0.55	-0.2	0.61	0.61	-0.4	0.9	0.75	0.52	0.07	0.75	0.41

Click cells to compare fundamentals

Redhill Biopharma Account Relationship Matchups

Redhill Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	74.1M	180.2M	181.2M	158.9M	23.0M	21.9M
Other Current Liab	107K	60.0M	68.2M	77.0M	15.2M	19.1M
Total Current Liabilities	10.6M	73.2M	81.5M	197.5M	19.2M	33.1M
Other Liab	844K	500K	7.9M	4.6M	5.3M	2.8M
Accounts Payable	4.2M	11.6M	11.7M	4.2M	3.3M	4.2M
Cash	29.0M	29.3M	29.5M	20.0M	5.6M	5.3M
Common Stock Shares Outstanding	742.3K	910.7K	1.2M	1.5M	6.5M	6.8M
Short Term Investments	24.2M	18.8M	498K	8.5M	790.0K	750.5K
Other Current Assets	2.2M	4.9M	3.8M	17.0M	2.1M	2.0M
Total Liab	14.1M	166.4M	172.3M	207.3M	21.0M	19.9M
Intangible Assets	16.9M	87.9M	71.6M	65.6M	5.6M	5.3M
Common Stock	962K	1.1M	1.5M	2.8M	21.4M	22.5M
Property Plant Equipment	163K	3.8M	5.7M	4.2M	4.9M	5.1M
Total Stockholder Equity	60.0M	13.9M	8.9M	(48.4M)	2.1M	2.0M
Property Plant And Equipment Net	3.8M	5.7M	4.2M	7.2M	1.2M	2.0M
Net Debt	(25.2M)	57.6M	58.3M	102.7M	(4.4M)	(4.2M)
Retained Earnings	(208.4M)	(280.3M)	(367.9M)	(433.9M)	(407.7M)	(387.4M)
Non Current Assets Total	20.9M	109.7M	92.0M	73.0M	6.9M	6.6M
Non Currrent Assets Other	(20.7M)	16.2M	16.2M	150K	41.0	38.95
Cash And Short Term Investments	47.9M	29.8M	38.0M	20.0M	6.4M	6.0M
Net Receivables	1.2M	29.3M	32.5M	37.9M	3.3M	3.1M
Common Stock Total Equity	575K	767K	962K	1.1M	1.2M	1.3M
Liabilities And Stockholders Equity	74.1M	180.2M	181.2M	158.9M	23.0M	21.9M
Non Current Liabilities Total	3.5M	93.1M	90.8M	9.8M	1.7M	1.6M
Inventory	1.9M	6.5M	14.8M	11.0M	4.4M	4.6M
Other Stockholder Equity	267.4M	293.1M	375.2M	382.6M	388.4M	217.0M
Property Plant And Equipment Gross	3.8M	5.7M	5.0M	8.3M	2.4M	2.2M
Total Current Assets	53.2M	70.5M	89.2M	85.9M	16.1M	15.3M
Net Tangible Assets	45.9M	43.1M	(74.0M)	(62.8M)	(56.5M)	(53.7M)
Net Invested Capital	60.0M	95.3M	92.5M	66.8M	2.1M	2.0M
Net Working Capital	42.6M	(2.7M)	7.7M	(111.6M)	(3.1M)	(2.9M)
Capital Stock	962K	1.1M	1.5M	2.8M	21.4M	22.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:

How To Invest In Redhill

Details

Is Redhill Stock a good investment?

Details

What is Redhill Biopharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.

You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(302.63)

Revenue Per Share

4.733

Quarterly Revenue Growth

(0.28)

Return On Assets

(0.45)

Return On Equity

(17.09)

The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Redhill Net Debt vs Accounts Payable Analysis

Net Debt vs Accounts Payable

Net Debt vs Accounts Payable Correlation Analysis

Correlation Coefficient

Net Debt

Accounts Payable

Redhill Biopharma fundamental ratios Correlations

Redhill Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Redhill Biopharma fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Receivables	+ 1.0	Total Liab
Non Current Assets Total	+ 1.0	Intangible Assets
Total Liab	+ 0.99	Other Current Liab
Net Receivables	+ 0.99	Other Current Liab
Common Stock	+ 0.99	Common Stock Shares Outstanding
Intangible Assets	+ 0.96	Total Liab

Common Stock Total Equity	- 0.96	Retained Earnings
Common Stock	- 0.95	Preferred Stock Total Equity
Preferred Stock Total Equity	- 0.93	Common Stock Shares Outstanding
Other Assets	- 0.92	Retained Earnings
Retained Earnings	- 0.9	Property Plant Equipment
Retained Earnings	- 0.9	Long Term Debt